Search Results - "Maris, M."

Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations by Bosse, Kristopher R., Maris, John M.

“…Neuroblastoma is an embryonal malignancy that commonly affects young children and is remarkably heterogenous in its malignant potential. Recently, the genetic…”
Get full text

Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group by Irwin, Meredith S, Naranjo, Arlene, Zhang, Fan F, Cohn, Susan L, London, Wendy B, Gastier-Foster, Julie M, Ramirez, Nilsa C, Pfau, Ruthann, Reshmi, Shalini, Wagner, Elizabeth, Nuchtern, Jed, Asgharzadeh, Shahab, Shimada, Hiroyuki, Maris, John M, Bagatell, Rochelle, Park, Julie R, Hogarty, Michael D

“…Treatment planning for children with neuroblastoma requires accurate assessment of prognosis. The most recent Children's Oncology Group (COG) risk…”
Get full text

11q deletion in neuroblastoma: a review of biological and clinical implications by Mlakar, Vid, Jurkovic Mlakar, Simona, Lopez, Gonzalo, Maris, John M, Ansari, Marc, Gumy-Pause, Fabienne

“…Deletion of the long arm of chromosome 11 (11q deletion) is one of the most frequent events that occur during the development of aggressive neuroblastoma…”
Get full text

MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells by Altman, Brian J., Hsieh, Annie L., Sengupta, Arjun, Krishnanaiah, Saikumari Y., Stine, Zachary E., Walton, Zandra E., Gouw, Arvin M., Venkataraman, Anand, Li, Bo, Goraksha-Hicks, Pankuri, Diskin, Sharon J., Bellovin, David I., Simon, M. Celeste, Rathmell, Jeffrey C., Lazar, Mitchell A., Maris, John M., Felsher, Dean W., Hogenesch, John B., Weljie, Aalim M., Dang, Chi V.

“…The MYC oncogene encodes MYC, a transcription factor that binds the genome through sites termed E-boxes (5′-CACGTG-3′), which are identical to the binding…”
Get full text

Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting by Park, Julie R, Bagatell, Rochelle, Cohn, Susan L, Pearson, Andrew D, Villablanca, Judith G, Berthold, Frank, Burchill, Susan, Boubaker, Ariane, McHugh, Kieran, Nuchtern, Jed G, London, Wendy B, Seibel, Nita L, Lindwasser, O Wolf, Maris, John M, Brock, Penelope, Schleiermacher, Gudrun, Ladenstein, Ruth, Matthay, Katherine K, Valteau-Couanet, Dominique

“…Purpose More than two decades ago, an international working group established the International Neuroblastoma Response Criteria (INRC) to assess treatment…”
Get full text

Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome by Padovan-Merhar, Olivia M, Raman, Pichai, Ostrovnaya, Irina, Kalletla, Karthik, Rubnitz, Kaitlyn R, Sanford, Eric M, Ali, Siraj M, Miller, Vincent A, Mossé, Yael P, Granger, Meaghan P, Weiss, Brian, Maris, John M, Modak, Shakeel

“…Neuroblastoma is characterized by a relative paucity of recurrent somatic mutations at diagnosis. However, recent studies have shown that the mutational burden…”
Get full text

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy by Sotillo, Elena, Barrett, David M, Black, Kathryn L, Bagashev, Asen, Oldridge, Derek, Wu, Glendon, Sussman, Robyn, Lanauze, Claudia, Ruella, Marco, Gazzara, Matthew R, Martinez, Nicole M, Harrington, Colleen T, Chung, Elaine Y, Perazzelli, Jessica, Hofmann, Ted J, Maude, Shannon L, Raman, Pichai, Barrera, Alejandro, Gill, Saar, Lacey, Simon F, Melenhorst, Jan J, Allman, David, Jacoby, Elad, Fry, Terry, Mackall, Crystal, Barash, Yoseph, Lynch, Kristen W, Maris, John M, Grupp, Stephan A, Thomas-Tikhonenko, Andrei

“…The CD19 antigen, expressed on most B-cell acute lymphoblastic leukemias (B-ALL), can be targeted with chimeric antigen receptor-armed T cells (CART-19), but…”
Get more information

Neuroblastoma by Maris, John M, MD, Hogarty, Michael D, MD, Bagatell, Rochelle, MD, Cohn, Susan L, Prof

“…Summary The clinical hallmark of neuroblastoma is heterogeneity, with the likelihood of cure varying widely according to age at diagnosis, extent of disease,…”
Get full text

Assessment of programmed death‐ligand 1 expression and tumor‐associated immune cells in pediatric cancer tissues by Majzner, Robbie G., Simon, Jason S., Grosso, Joseph F., Martinez, Daniel, Pawel, Bruce R., Santi, Mariarita, Merchant, Melinda S., Geoerger, Birgit, Hezam, Imene, Marty, Virginie, Vielh, Phillippe, Daugaard, Mads, Sorensen, Poul H., Mackall, Crystal L., Maris, John M.

“…BACKGROUND Programmed death 1 (PD‐1) signaling in the tumor microenvironment dampens immune responses to cancer, and blocking this axis induces antitumor…”
Get full text

Children's Oncology Group's 2013 blueprint for research: Neuroblastoma by Park, Julie R., Bagatell, Rochelle, London, Wendy B., Maris, John M., Cohn, Susan L., Mattay, Katherine M., Hogarty, Michael

“…Estimated 5‐year survival rates for patients with non‐high‐risk and high‐risk neuroblastoma are 90% and 50%, respectively. Recent clinical trials have shown…”
Get full text

Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations by Brady, Samuel W., Liu, Yanling, Ma, Xiaotu, Gout, Alexander M., Hagiwara, Kohei, Zhou, Xin, Wang, Jian, Macias, Michael, Chen, Xiaolong, Easton, John, Mulder, Heather L., Rusch, Michael, Wang, Lu, Nakitandwe, Joy, Lei, Shaohua, Davis, Eric M., Naranjo, Arlene, Cheng, Cheng, Maris, John M., Downing, James R., Cheung, Nai-Kong V., Hogarty, Michael D., Dyer, Michael A., Zhang, Jinghui

“…Neuroblastoma is a pediatric malignancy with heterogeneous clinical outcomes. To better understand neuroblastoma pathogenesis, here we analyze whole-genome,…”
Get full text

Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial by Mody, Rajen, MD, Naranjo, Arlene, PhD, Van Ryn, Collin, MS, Yu, Alice L, Prof, London, Wendy B, PhD, Shulkin, Barry L, Prof, Parisi, Marguerite T, Prof, Servaes, Sabah-E-Noor, MD, Diccianni, Mitchell B, PhD, Sondel, Paul M, Prof, Bender, Julia G, MD, Maris, John M, Prof, Park, Julie R, Prof, Bagatell, Rochelle, Dr

“…Summary Background Outcomes for children with relapsed and refractory neuroblastoma are dismal. The combination of irinotecan and temozolomide has activity in…”
Get full text

Identification of SARS-CoV-2 Vaccine Epitopes Predicted to Induce Long-Term Population-Scale Immunity by Yarmarkovich, Mark, Warrington, John M., Farrel, Alvin, Maris, John M.

“…Here we propose a SARS-CoV-2 vaccine design concept based on identification of highly conserved regions of the viral genome and newly acquired adaptations,…”
Get full text

Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma by RADER, Julieann, RUSSELL, Mike R, SUNKYU KIM, PARASURAMAN, Sudha, CAPONIGRO, Giordano, SCHNEPP, Robert W, WOOD, Andrew C, PAWEL, Bruce, COLE, Kristina A, MARIS, John M, HART, Lori S, NAKAZAWA, Michael S, BELCASTRO, Lili T, MARTINEZ, Daniel, YIMEI LI, CARPENTER, Erica L, ATTIYEH, Edward F, DISKIN, Sharon J

“…Neuroblastoma is a pediatric cancer that continues to exact significant morbidity and mortality. Recently, a number of cell-cycle proteins, particularly those…”
Get full text

Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism by Oldridge, Derek A., Wood, Andrew C., Weichert-Leahey, Nina, Crimmins, Ian, Sussman, Robyn, Winter, Cynthia, McDaniel, Lee D., Diamond, Maura, Hart, Lori S., Zhu, Shizhen, Durbin, Adam D., Abraham, Brian J., Anders, Lars, Tian, Lifeng, Zhang, Shile, Wei, Jun S., Khan, Javed, Bramlett, Kelli, Rahman, Nazneen, Capasso, Mario, Iolascon, Achille, Gerhard, Daniela S., Guidry Auvil, Jaime M., Young, Richard A., Hakonarson, Hakon, Diskin, Sharon J., Thomas Look, A., Maris, John M.

“…A causal variant is identified at the LMO1 oncogene locus that drives the genetic association of LMO1 with neuroblastoma susceptibility; the causal SNP…”
Get full text

Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma by Bosse, Kristopher R., Raman, Pichai, Zhu, Zhongyu, Lane, Maria, Martinez, Daniel, Heitzeneder, Sabine, Rathi, Komal S., Kendsersky, Nathan M., Randall, Michael, Donovan, Laura, Morrissy, Sorana, Sussman, Robyn T., Zhelev, Doncho V., Feng, Yang, Wang, Yanping, Hwang, Jennifer, Lopez, Gonzalo, Harenza, Jo Lynne, Wei, Jun S., Pawel, Bruce, Bhatti, Tricia, Santi, Mariarita, Ganguly, Arupa, Khan, Javed, Marra, Marco A., Taylor, Michael D., Dimitrov, Dimiter S., Mackall, Crystal L., Maris, John M.

“…We developed an RNA-sequencing-based pipeline to discover differentially expressed cell-surface molecules in neuroblastoma that meet criteria for optimal…”
Get full text

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study by Mossé, Yael P, Dr, Lim, Megan S, MD, Voss, Stephan D, MD, Wilner, Keith, PhD, Ruffner, Katherine, MD, Laliberte, Julie, Rolland, Delphine, Balis, Frank M, Prof, Maris, John M, Prof, Weigel, Brenda J, MD, Ingle, Ashish M, MS, Ahern, Charlotte, PhD, Adamson, Peter C, Prof, Blaney, Susan M, Prof

“…Summary Background Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma,…”
Get full text

ATF4 Regulates MYC-Mediated Neuroblastoma Cell Death upon Glutamine Deprivation by Qing, Guoliang, Li, Bo, Vu, Annette, Skuli, Nicolas, Walton, Zandra E., Liu, Xueyuan, Mayes, Patrick A., Wise, David R., Thompson, Craig B., Maris, John M., Hogarty, Michael D., Simon, M. Celeste

“…Oncogenic Myc alters mitochondrial metabolism, making it dependent on exogenous glutamine (Gln) for cell survival. Accordingly, Gln deprivation selectively…”
Get full text

New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient Outcome by COLE, Kristina A, MARIS, John M

“…Neuroblastoma remains responsible for a disproportionate amount of childhood cancer morbidity and mortality despite recent significant advances in…”
Get full text

ROGUE: an R Shiny app for RNA sequencing analysis and biomarker discovery by Farrel, Alvin, Li, Peng, Veenbergen, Sharon, Patel, Khushbu, Maris, John M, Leonard, Warren J

“…The growing power and ever decreasing cost of RNA sequencing (RNA-Seq) technologies have resulted in an explosion of RNA-Seq data production. Comparing gene…”
Get full text